Related references
Note: Only part of the references are listed.A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Synovial CD4+T-cell-derived GM-CSF supports the differentiation of an inflammatory dendritic cell population in rheumatoid arthritis
G. Reynolds et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor a inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study
Josef S. Smolen et al.
ARTHRITIS RESEARCH & THERAPY (2015)
Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
Jonathan Kay et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis
D. E. A. Greven et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis
Lisa M. Lundquist et al.
WORLD JOURNAL OF ORTHOPEDICS (2014)
Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis
Manuela Di Franco et al.
CORE EVIDENCE (2014)
Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Protein engineering and preclinical development of a GM-CSF receptor antibody for the treatment of rheumatoid arthritis
R. R. Minter et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment
Paul Emery
RHEUMATOLOGY (2012)
Covariate-adjusted Difference in Proportions From Clinical Trials Using Logistic Regression and Weighted Risk Differences
Miaomiao Ge et al.
DRUG INFORMATION JOURNAL (2011)
MECHANISMS OF DISEASE The Pathogenesis of Rheumatoid Arthritis
Iain B. McInnes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Greater Likelihood of Remission in Rheumatoid Arthritis Patients Treated Earlier in the Disease Course: Results From the Consortium of Rheumatology Researchers of North America Registry
Daniel E. Furst et al.
ARTHRITIS CARE & RESEARCH (2011)
Pulmonary alveolar proteinosis
R. Borie et al.
EUROPEAN RESPIRATORY REVIEW (2011)
Golimumab inpatients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
Josef S. Smolen et al.
LANCET (2009)
Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review
Andrea Rubbert-Roth et al.
ARTHRITIS RESEARCH & THERAPY (2009)
Rare lung diseases II: Pulmonary alveolar proteinosis
Stephen C. Juvet et al.
CANADIAN RESPIRATORY JOURNAL (2008)
Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study
Daniel E. Furst et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score
D Aletaha et al.
ARTHRITIS RESEARCH & THERAPY (2005)
A simplified disease activity index for rheumatoid arthritis for use in clinical practice
JS Smolen et al.
RHEUMATOLOGY (2003)
Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate - The ARMADA trial
ME Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2003)
Share Paper
